All In Biotech

Drug Trial Radar · NCT06047457

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Episodic Migraine in Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 751 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

751

Actual

Start

Sep 29, 2023

Primary completion

Jun 1, 2026

Study completion Nov 16, 2026

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).

Conditions

  • Episodic Migraine

Interventions

  • Botulinum toxin type ABiological

    Dose "A" U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.

  • Botulinum toxin type ABiological

    Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.

  • PlaceboOther

    "0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.

  • Botulinum toxin type ABiological

    Dose "A" U/I, IM on Week 24 and Week 36 with a total of 2 injections.

  • Botulinum toxin type ABiological

    Dose "B" U/I, IM on Week 24 and Week 36 with a total of 2 injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in monthly migraine days (MMD)Time frame: Every 4 weeks from Week 4 (Weeks 1-4) to Week 24 (Weeks 21-24)

Locations

105 sites in 8 countries. Site status is shown where the registry gives one.

  • Central Research Associates

    Birmingham, Alabama

  • CCT Research

    Phoenix, Arizona

  • HonorHealth Neurology

    Scottsdale, Arizona

  • Hope Clinical Research, LLC

    Canoga Park, California

  • Axiom Research LLC

    Colton, California

  • Fullerton Neurological Center

    Fullerton, California

  • Neurology Center of North Orange County

    Fullerton, California

  • SDS Clinical Trials

    Orange, California

  • Alliance Clinical San Diego (Acclaim Clinical Research)

    San Diego, California

  • The Los Angeles Headache Center

    Savannah, California

  • Yale University School of Medicine

    East Hartford, Connecticut

  • Hasbani Neurology

    New Haven, Connecticut

  • New England Institute for Neurology and Headache (NEINH)/Medical Practice

    Stamford, Connecticut

  • Visionary Investigators Network (VIN)

    Aventura, Florida

  • Velocity Clinical Research - Hallandale Beach

    Hallandale, Florida

  • AGA Clinical Trials

    Hialeah, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Clinical Neuroscience Solutions Healthcare, Inc (CNS Healthcare, INC)

    Jacksonville, Florida

  • 840042

    Miami, Florida

  • Quantum Clinical Trials

    Miami Beach, Florida

  • Clinical Neuroscience Solutions, Inc ((CNS Healthcare) - Psychiatry)

    Orlando, Florida

  • Guardian Angel Research Center

    Tampa, Florida

  • Boston Clinical Trials Inc

    Winter Park, Florida

  • Conquest Research

    Winter Park, Florida

  • Cedar Crosse Research Center

    Chicago, Illinois

  • Chicago Headache Center & Research Institute

    Chicago, Illinois

  • Robbins Headache Clinic

    Riverwoods, Illinois

  • MD Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • Comprehensive Neurology Services

    Frederick, Maryland

  • Boston Clinical Trials Inc

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center - Arnold Pain Management

    Brookline, Massachusetts

  • Neurology Center of NE,PC - Neurology

    Foxborough, Massachusetts

  • Lone Star Neurology,

    Westborough, Massachusetts

  • New England Regional Headache Center, Inc.

    Worcester, Massachusetts

  • Quest Research Institute

    Farmington Hills, Michigan

  • Minneapolis Clinic of Neurology

    Burnsville, Minnesota

  • Clinical Research Professionals

    Chesterfield, Missouri

  • M3 Wake Research - Las Vegas Wellness Way

    Las Vegas, Nevada

  • Alliance Clinical Las Vegas (Excel Clinical Research)

    Las Vegas, Nevada

  • SPRI Clinical Trials, LLC

    Brooklyn, New York

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.